查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1513337

植入市场：按类型、最终用户划分：2024-2035 年全球机会分析与产业预测

Bioimplants Market By Type, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
2023年，全球植入市场价值为132​​8亿美元，预计2024年至2035年复合年增长率为8.8%，到2035年达到3648亿美元。植入，也称为生物医学植入，是放置在体内或体表的装置或组织，用于替代或支持生物结构、监测身体功能、输送药物或治疗性介入。这些植入旨在与人体组织和系统无缝集成，旨在改善患有各种疾病的人们的健康结果和生活品质。植入可由多种材料製成，包括金属、陶瓷、聚合物以及组织和细胞等生物材料。它们被用于广泛的医疗应用，包括整形外科（例如髋关节和膝关节置换术）、介入心臟病学（例如支架和心律调节器）、神经病学（例如深层脑部刺激器），甚至整容手术（例如乳房植入） ）。
生物植入市场-IMG1
植入市场的成长归因于老年人口的增加、心血管疾病盛行率的快速增加以及植入技术的进步。老年人口的增加是推动植入市场向前发展的关键驱动力。医疗保健的进步和整体生活品质的改善使人们的寿命比以往任何时候都更长。结果，世界人口中老年人的比例显着增加。根据世界卫生组织（WHO）预计，到2050年，60岁及以上的人口将占世界人口的22%。老年人经常面临退化性疾病、骨骼脆弱和牙齿健康不佳等挑战，需要关节重建、骨移植和人工植牙等治疗。植入提供了一种创新方法来恢復这些患者的功能、减轻疼痛并提高整体生活品质。此外，随着老年人口的持续增加，对植入的需求也预计会相应增加，从而推动市场扩张。心血管疾病的迅速增加已成为推动植入市场成长的关键驱动力。美国疾病管制与预防美国2023 年发表的一篇报导报告称，心臟病是美国男性和女性死亡的主要原因。随着心血管疾病在全球日益流行，对有效解决这些疾病的创新解决方案的需求不断增长。植入，包括心律调节器、支架和人工心臟瓣膜等各种装置，在心血管疾病的管理和治疗中发挥着至关重要的作用。与传统治疗方法相比，这些植入具有多种优势，包括延长寿命、降低併发症风险和改善患者治疗效果。此外，生物材料和生物技术的进步促进了生物植入的发展，这些植入物非常模仿自然组织，有助于更好地融入体内并最大限度地降低排斥风险。因此，医疗保健提供者越来越多地将植入作为治疗心血管疾病的首选，而推动市场成长的技术进步已成为推动植入市场成长的至关重要的驱动力。这些进步包括从材料科学到小型化再到先进製造技术的创新。关键进展之一是开发具有增强的生物相容性、耐用性和功能性的生物材料。这些材料，例如可生物分解性聚合物和生物活性陶瓷，可与生物系统无缝集成，降低排斥风险并改善患者的长期治疗效果。此外，积层製造（通常称为 3D 列印）的进步彻底改变了针对个别患者解剖结构量身自订的植入的生产。这不仅提高了植入的有效性，而且简化了手术过程，减少了手术时间并最大限度地减少了术后併发症。随着这些技术创新的不断发展，植入在不同医疗领域的应用和功效有望进一步扩大。植入市场按类型、最终用户和地区细分。按类型划分，植入市场分为心血管植入、牙科植入、整形外科植入、脊椎植入、眼科植入和其他植入。依最终用户划分，可分为医院、专科诊所和门诊手术中心。依地区划分，北美（美国）、北美洲（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、其他欧洲国家地区）、亚太地区（日本、中国、澳洲、印度、韩国、其他欧洲地区）、亚太地区）、亚太地区（巴西、沙乌地阿拉伯、南非和亚洲其他地区）。植入市场的主要企业包括美敦力公司、史赛克公司、强生公司（爱惜康公司）、雅培实验室（圣裘德医疗公司）、登士柏西诺德公司、波士顿科学公司和威格斯主要企业。​​

相关人员的主要利益

  • 该报告提供了 2023 年至 2035 年生物医学植入市场分析的细分市场、当前趋势、估计和动态的定量分析，并确定了有前景的生物医学植入市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的潜力。
  • 植入市场细分的详细分析将有助于确定市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前位置的清晰了解。
  • 该研究报告包括对区域和全球植入市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章植入市场：依类型

  • 概述
  • 心血管植入
  • 牙科植入
  • 整形外科植入
  • 脊椎植入
  • 眼科植入
  • 其他植入

第五章植入市场：依最终用户分类

  • 概述
  • 医院
  • 专科诊所
  • 门诊手术中心

第六章植入市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2023年主要企业定位

第八章 公司简介

  • Stryker Corporation
  • Medtronic plc
  • Smith & Nephew plc
  • Dentsply Sirona Inc.
  • Johnson & Johnson
  • Victrex plc
  • Zimmer Biomet Holdings Inc.
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Arthrex, Inc.
Product Code: A04298
The global bioimplants market was valued at $132.80 billion in 2023 and is projected to reach $364.8 billion by 2035, growing at a CAGR of 8.8% from 2024 to 2035. Bioimplants, also known as biomedical implants, are devices or tissues that are placed inside or on the surface of the body to replace or support biological structures, monitor bodily functions, deliver drugs, or provide therapeutic interventions. These implants are designed to integrate seamlessly with the body's tissues and systems, aiming to improve health outcomes and quality of life for individuals with various medical conditions. Bioimplants can be made from a variety of materials, including metals, ceramics, polymers, and biological substances such as tissues or cells. They are utilized in a wide range of medical applications, including orthopedics (such as hip or knee replacements), cardiovascular interventions (such as stents or pacemakers), neurology (such as deep brain stimulation devices), and even in cosmetic surgery (such as breast implants).
Bioimplants Market - IMG1
The bioimplants market growth is attributed to rise in geriatric population, surge in prevalence of cardiovascular diseases, and technological advancement in bioimplant technology. The rise in the geriatric population stands as a significant driver propelling the bioimplants market forward. With advancements in healthcare and improvements in overall quality of life, people are living longer than ever before. As a result, there has been a notable increase in the proportion of elderly individuals within the global population. According to World Health Organization it was estimated that by 2050 proportion of the world's population over 60 years will be 22% of global population.Elderly individuals often face challenges such as degenerative joint diseases, weakened bones, and deteriorating dental health, necessitating interventions such as joint replacements, bone grafts, and dental implants. Bioimplants offer innovative approaches to restore functionality, alleviate pain, and improve the overall quality of life for these patients. Furthermore, as the geriatric population continues to grow, the demand for bioimplants is expected to escalate correspondingly, driving market expansion. Thus, the rise in geriatric population is expected to drive the growth of the market.The surge in cardiovascular diseases has emerged as a significant driving force propelling the growth of bioimplants market. According to 2023 article by Center of Disease Control and Prevention it was reported that Heart disease is the leading cause of death for men, women in U.S. With cardiovascular diseases increasingly prevalent globally, there has been a heightened demand for innovative solutions to address these conditions effectively. Bioimplants, which encompass a range of devices such as pacemakers, stents, and artificial heart valves, play a pivotal role in managing and treating cardiovascular ailments. These implants offer several advantages over traditional treatments, including improved longevity, reduced risk of complications, and enhanced patient outcomes. Moreover, advancements in biomaterials and biotechnology have led to the development of bioimplants that closely mimic natural tissues, promoting better integration within the body and minimizing the risk of rejection. As a result, healthcare providers are increasingly turning to bioimplants as a preferred option for managing cardiovascular diseases, driving the growth of the marketTechnological advancements have emerged as a pivotal force propelling the growth of the bioimplants market. These advancements encompass a spectrum of innovations, ranging from materials science to miniaturization and advanced manufacturing techniques. One significant stride lies in the development of biomaterials with enhanced biocompatibility, durability, and functionality. These materials, such as biodegradable polymers and bioactive ceramics, enable seamless integration with biological systems, reducing the risk of rejection and improving long-term outcomes for patients. Moreover, advancements in additive manufacturing, commonly known as 3D printing, have revolutionized the production of custom-designed implants tailored to individual patient anatomy. This not only enhances the efficacy of implants but also streamlines the surgical process, reducing operating time and minimizing post-operative complications. As these technological innovations continue to evolve, they hold the promise of further expanding the application and efficacy of bioimplants across diverse medical fields.The bioimplants market is segmented on the basis of type, end user, and region. By type the market is divided into cardiovascular bioimplants, dental bioimplants, orthopedic bioimplants, spinal bioimplants, ophthalmology bioimplants, other bioimplants. By end user, the market is classified into hospital, specialized clinics, and ambulatory surgical centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).Major key players that operate in the bioimplants market are Medtronic plc, Stryker Corporation, Johnson & Johnson (Ethicon, Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Dentsply Sirona Inc, Boston Scientific Corporation, Victrex Plc. (Invibio Ltd.), Smith & Nephew plc, Arthrex, Inc, Zimmer Biomet Holdings Inc. Key players have adopted product approval as a key developmental strategy to improve the product portfolio of the bioimplants market

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bioimplants market analysis from 2023 to 2035 to identify the prevailing bioimplants market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the bioimplants market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global bioimplants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Dental bioimplants
  • Orthopedic bioimplants
  • Spinal bioimplants
  • Ophthalmology bioimplants
  • Cardiovascular bioimplants
  • Other bioimplants

By End User

  • Hospitals
  • Specialty clinics
  • Ambulatory surgical centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Stryker Corporation
    • Medtronic plc
    • Smith & Nephew plc
    • Dentsply Sirona Inc.
    • Johnson & Johnson
    • Victrex plc
    • Zimmer Biomet Holdings Inc.
    • Boston Scientific Corporation
    • Abbott Laboratories
    • Arthrex, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BIOIMPLANTS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Cardiovascular bioimplants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Dental bioimplants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Orthopedic bioimplants
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Spinal bioimplants
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Ophthalmology bioimplants
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Other bioimplants
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country

CHAPTER 5: BIOIMPLANTS MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Specialty clinics
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Ambulatory surgical centers
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: BIOIMPLANTS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Type
      • 6.3.4.5.2. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Type
      • 6.3.4.6.2. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by End User
      • 6.4.4.3. India
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by End User
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Type
      • 6.5.4.3.2. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Type
      • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Stryker Corporation
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. Medtronic plc
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Smith & Nephew plc
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Dentsply Sirona Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Johnson & Johnson
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Victrex plc
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Zimmer Biomet Holdings Inc.
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Boston Scientific Corporation
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Abbott Laboratories
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Arthrex, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 02. BIOIMPLANTS MARKET FOR CARDIOVASCULAR BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 03. BIOIMPLANTS MARKET FOR DENTAL BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 04. BIOIMPLANTS MARKET FOR ORTHOPEDIC BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 05. BIOIMPLANTS MARKET FOR SPINAL BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 06. BIOIMPLANTS MARKET FOR OPHTHALMOLOGY BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 07. BIOIMPLANTS MARKET FOR OTHER BIOIMPLANTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 08. GLOBAL BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 09. BIOIMPLANTS MARKET FOR HOSPITALS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 10. BIOIMPLANTS MARKET FOR SPECIALITY CLINICS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 11. BIOIMPLANTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 12. BIOIMPLANTS MARKET, BY REGION, 2023-2035 ($MILLION)
  • TABLE 13. NORTH AMERICA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 14. NORTH AMERICA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 15. NORTH AMERICA BIOIMPLANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 16. U.S. BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 17. U.S. BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 18. CANADA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 19. CANADA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 20. MEXICO BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 21. MEXICO BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 22. EUROPE BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 23. EUROPE BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 24. EUROPE BIOIMPLANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 25. GERMANY BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 26. GERMANY BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 27. FRANCE BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 28. FRANCE BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 29. UK BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 30. UK BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 31. ITALY BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 32. ITALY BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 33. SPAIN BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 34. SPAIN BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 35. REST OF EUROPE BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 36. REST OF EUROPE BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 37. ASIA-PACIFIC BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 38. ASIA-PACIFIC BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 39. ASIA-PACIFIC BIOIMPLANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 40. JAPAN BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 41. JAPAN BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 42. CHINA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 43. CHINA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 44. INDIA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 45. INDIA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 46. AUSTRALIA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 47. AUSTRALIA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 48. SOUTH KOREA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 49. SOUTH KOREA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 50. REST OF ASIA-PACIFIC BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 51. REST OF ASIA-PACIFIC BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 52. LAMEA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 53. LAMEA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 54. LAMEA BIOIMPLANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 55. BRAZIL BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 56. BRAZIL BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 57. SAUDI ARABIA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 58. SAUDI ARABIA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 59. SOUTH AFRICA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 60. SOUTH AFRICA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 61. REST OF LAMEA BIOIMPLANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
  • TABLE 62. REST OF LAMEA BIOIMPLANTS MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 63. STRYKER CORPORATION: KEY EXECUTIVES
  • TABLE 64. STRYKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 65. STRYKER CORPORATION: PRODUCT SEGMENTS
  • TABLE 66. STRYKER CORPORATION: SERVICE SEGMENTS
  • TABLE 67. STRYKER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 68. STRYKER CORPORATION: KEY STRATEGIES
  • TABLE 69. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 70. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 71. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 72. MEDTRONIC PLC: SERVICE SEGMENTS
  • TABLE 73. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 74. MEDTRONIC PLC: KEY STRATEGIES
  • TABLE 75. SMITH & NEPHEW PLC: KEY EXECUTIVES
  • TABLE 76. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
  • TABLE 77. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
  • TABLE 78. SMITH & NEPHEW PLC: SERVICE SEGMENTS
  • TABLE 79. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
  • TABLE 80. SMITH & NEPHEW PLC: KEY STRATEGIES
  • TABLE 81. DENTSPLY SIRONA INC.: KEY EXECUTIVES
  • TABLE 82. DENTSPLY SIRONA INC.: COMPANY SNAPSHOT
  • TABLE 83. DENTSPLY SIRONA INC.: PRODUCT SEGMENTS
  • TABLE 84. DENTSPLY SIRONA INC.: SERVICE SEGMENTS
  • TABLE 85. DENTSPLY SIRONA INC.: PRODUCT PORTFOLIO
  • TABLE 86. DENTSPLY SIRONA INC.: KEY STRATEGIES
  • TABLE 87. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 88. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 89. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 90. JOHNSON & JOHNSON: SERVICE SEGMENTS
  • TABLE 91. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 92. JOHNSON & JOHNSON: KEY STRATEGIES
  • TABLE 93. VICTREX PLC: KEY EXECUTIVES
  • TABLE 94. VICTREX PLC: COMPANY SNAPSHOT
  • TABLE 95. VICTREX PLC: PRODUCT SEGMENTS
  • TABLE 96. VICTREX PLC: SERVICE SEGMENTS
  • TABLE 97. VICTREX PLC: PRODUCT PORTFOLIO
  • TABLE 98. VICTREX PLC: KEY STRATEGIES
  • TABLE 99. ZIMMER BIOMET HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 100. ZIMMER BIOMET HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 101. ZIMMER BIOMET HOLDINGS INC.: PRODUCT SEGMENTS
  • TABLE 102. ZIMMER BIOMET HOLDINGS INC.: SERVICE SEGMENTS
  • TABLE 103. ZIMMER BIOMET HOLDINGS INC.: PRODUCT PORTFOLIO
  • TABLE 104. ZIMMER BIOMET HOLDINGS INC.: KEY STRATEGIES
  • TABLE 105. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 106. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 107. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 108. BOSTON SCIENTIFIC CORPORATION: SERVICE SEGMENTS
  • TABLE 109. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 110. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIES
  • TABLE 111. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 112. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 113. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 114. ABBOTT LABORATORIES: SERVICE SEGMENTS
  • TABLE 115. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 116. ABBOTT LABORATORIES: KEY STRATEGIES
  • TABLE 117. ARTHREX, INC.: KEY EXECUTIVES
  • TABLE 118. ARTHREX, INC.: COMPANY SNAPSHOT
  • TABLE 119. ARTHREX, INC.: PRODUCT SEGMENTS
  • TABLE 120. ARTHREX, INC.: SERVICE SEGMENTS
  • TABLE 121. ARTHREX, INC.: PRODUCT PORTFOLIO
  • TABLE 122. ARTHREX, INC.: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. BIOIMPLANTS MARKET, 2023-2035
  • FIGURE 02. SEGMENTATION OF BIOIMPLANTS MARKET,2023-2035
  • FIGURE 03. TOP IMPACTING FACTORS IN BIOIMPLANTS MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN BIOIMPLANTS MARKET (2024-2035)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL BIOIMPLANTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. BIOIMPLANTS MARKET, BY TYPE, 2023 AND 2035(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR CARDIOVASCULAR BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR DENTAL BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR ORTHOPEDIC BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR SPINAL BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR OPHTHALMOLOGY BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR OTHER BIOIMPLANTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 18. BIOIMPLANTS MARKET, BY END USER, 2023 AND 2035(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR SPECIALITY CLINICS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOIMPLANTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 22. BIOIMPLANTS MARKET BY REGION, 2023 AND 2035(%)
  • FIGURE 23. U.S. BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 24. CANADA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 25. MEXICO BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 26. GERMANY BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 27. FRANCE BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 28. UK BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 29. ITALY BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 30. SPAIN BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 31. REST OF EUROPE BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 32. JAPAN BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 33. CHINA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 34. INDIA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 35. AUSTRALIA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 36. SOUTH KOREA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 38. BRAZIL BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 39. SAUDI ARABIA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 40. SOUTH AFRICA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 41. REST OF LAMEA BIOIMPLANTS MARKET, 2023-2035 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: BIOIMPLANTS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2023